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Autism spectrum disorder and celiac disease: 
no evidence for a link
Transtorno autístico e doença celíaca: sem evidências de associação
Icaro Camargo Batista1, Lenora Gandolfi2, Yanna Karla Medeiros Nobrega3, Rodrigo Coutinho Almeida4, 
Lucas Malta Almeida5, Dioclécio Campos Junior1, Riccardo Pratesi2
Autism is a disorder of neural development character-
ized by impaired social interaction and communication, and 
by restricted and repetitive behavior. It is one of the three 
recognized autism spectrum disorders (ASDs); the other two 
are Asperger’s syndrome, which lacks delays in cognitive de-
velopment and language, and pervasive developmental dis-
order – not otherwise specified (commonly abbreviated as 
PDD-NOS), which is diagnosed when the full set of crite-
ria for autism or Asperger’s syndrome is not met1. Children 
with ASD frequently display tendencies toward self-harm, 
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AbstrAct
Objective: To evaluate the possible association between celiac disease (CD) and/or gluten sensitivity (GS) and autism spectrum disorder 
(ASD). Methods: Occurrences of CD were determined in a group of children and adolescents affected by ASD and, conversely, occurrences 
of ASD were assessed in a group of biopsy-proven celiac patients. To detect the possible existence of GS, the levels of antigliadin antibod-
ies in ASD patients were assessed and compared with the levels in a group of non-celiac children. Results: The prevalence of CD or GS in 
ASD patients was not greater than in groups originating from the same geographical area. Similarly the prevalence of ASD was not greater 
than in a group of biopsy-proven CD patients. Conclusion: No statistically demonstrable association was found between CD or GS and ASD. 
Consequently, routine screening for CD or GS in all patients with ASD is, at this moment, neither justified nor cost-effective.
Key words: autistic spectrum disorder, celiac disease, prevalence, mass screening.
resumo
Objetivo: Avaliar a possível associação entre doença celíaca (DC) e/ou sensibilidade ao glúten (SG) e transtorno do espectro autista (TEA). 
Métodos: Ocorrências de DC foram determinadas em um grupo de crianças e adolescentes afetados pelo TEA e a ocorrência d TEA foi 
avaliada em um grupo de pacientes com DC comprovada por biópsia. Para detectar a possível existência de SG, foram determinados níveis 
de anticorpos antigliadina em pacientes com TEA e comparados ao grupo de crianças sem a doença celíaca. Resultados: A prevalência de 
DC ou SG não foi maior no grupo de pacientes com TEA quando comparada a grupos de indivíduos originários da mesma região geográfica. 
De modo similar, a prevalência do TEA não foi maior ao ser comparada ao grupo de pacientes com DC. Conclusão: Não houve associação 
estatisticamente demonstrável entre DC ou SG e TEA. Consequentemente, não são justificáveis, no momento, exames de rotina para de-
tecção de DC ou SG em pacientes com TEA. 
Palavras-Chave: transtorno autístico, doença celíaca, prevalência, programa de rastreamento.
irritability, hyperactivity, erratic and aggressive behavior. 
One of the most confounding aspects of ASDs is their wide 
phenotypic heterogeneity, which suggests that ASDs may 
possibly encompass several different and specific disorders 
with different etiologies sharing a common behavioral clini-
cal picture. Although the cause of ASDs and their associated 
symptoms remain unclear, it is likely that their complex eti-
ology arises from the combined effects of multiple suscepti-
bility alleles in concert with environmental or other non-ge-
netic factors. Evidence from twin and family studies clearly 
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establishes the importance of genetic factors in the develop-
ment of ASDs2. 
ASDs were considered to be rare until a few decades ago, 
but their prevalence has increased more than tenfold over 
the past 20 years. Their estimated prevalence is 0.9% in the 
United States3, although data from a recent review of 47 stud-
ies conducted in 17 different countries since 1966 found that 
the prevalence ranged from 0.6 to 0.7%, or one child in about 
150 children4. In spite of the controversy regarding whether 
this is a real rise in the number of cases or the result of in-
creased publicity and better diagnostic criteria, it remains 
clear that ASDs are disorders that produce major challenges 
for the families and society. No reliable studies focusing on 
the prevalence of ASDs have been conducted in Brazil. 
Although celiac disease (CD) is classically defined as an 
immune-mediated chronic small-intestinal enteropathy, 
which is triggered by the ingestion of gluten from wheat, bar-
ley and rye in genetically predisposed individuals, CD could 
be more appropriately described as a multisystem disorder, 
often showing extra-intestinal symptoms and potentially af-
fecting any organ or body system, including the nervous sys-
tem5. The diagnosis of CD is traditionally based on positive 
serological tests and on a biopsy of the upper small intestine 
revealing varying degrees of villous atrophy, crypt hyperpla-
sia, and intraepithelial lymphocytes. The serological tests 
commonly used are the IgA-endomysial antibody (IgA-EMA), 
which possesses specificity approaching 100%, and the IgA-
anti-transglutaminase antibody (IgA-tTG), which does not 
have the same specificity but, since it is an enzyme-linked im-
munosorbent immunoassay (ELISA), it is less expensive and 
less observer-dependent6.
The association between CD and central nervous system 
dysfunction was initially suggested several decades ago by 
Cooke and Thomas-Smith7, and their initial review was fol-
lowed by numerous articles and case reports on patients with 
established CD and different neurological manifestations, in-
cluding neuropathy, ataxia, migraines and epilepsy8,9.
Some authors have raised the hypothesis that gluten sen-
sitivity may exist in patients with normal jejunal mucosa 
and negative anti-transglutaminase (IgA-tTG) and IgA-EMA 
tests. IgA-EMA and IgA-tTG detections are specific for the 
presence of enteropathy and are excellent indicators of CD. 
However, these markers are often not detectable in patients 
with neurological manifestations, particularly in the absence 
of enteropathy. Although there is not always a diagnostic for 
gluten sensitivity, the presence of positive antigliadin anti-
body (IgA-AGA) tests in these patients would raise a high de-
gree of suspicion and could be considered as an indicator for 
further testing and follow-up10.
Screening studies performed over the last decade in 
Brazil have shown uneven prevalence rates for CD in differ-
ent regions of Brazil, ranging from 1:52 to 1:417 in the general 
population11,12 and from 1:214 to 1:681 in presumably healthy 
blood donors13,14. Among children younger than 15 years-old, 
originating from the same geographical region and pertain-
ing to a similar socioeconomic stratum in which the pres-
ent study was performed, a prevalence of 1:185 (0.54%) was 
found12. Consequently, it seems that CD prevalence in Brazil 
is similar to what was found in European countries and in the 
USA, where an overall prevalence ranging from 1:150 to 1:250 
is generally accepted15. 
Increased presence of gastrointestinal disorders in ASD 
patients is a recurring theme, both in the medical literature 
and among the parents and caregivers of autistic children. 
Several studies have reported that gluten-free and casein-
free diets ameliorated autistic symptoms, although sound ev-
idence that this association really exists and complete agree-
ment among authors regarding this topic is still lacking16-19. 
Similarly, over the past decade, several authors have suggest-
ed that links may exist between CD and ASDs20 and between 
CD or gluten sensitivity and psychiatric disorders21,22, but 
these indications have been contradicted by other reports23.
The aims of the present study were to evaluate the exis-
tence of a possible relationship between CD or gluten sensi-
tivity and ASD, to determine occurrences of CD and/or in-
creased levels of IgA-AGA among a group of children and 
adolescents affected by ASD and, conversely, to assess oc-
currences of ASD among a group of biopsy-proven celiac 
patients.
metHoDs
The relationship between ASD and CD or ASD and glu-
ten sensitivity was assessed by evaluating a group of 147 pa-
tients with ASD for simultaneous occurrences of CD and/or 
increased levels of IgA-AGA. Conversely, occurrences of ASD 
were assessed in a group of 211 celiac patients followed-up at 
the Walk-in CD Clinic of the Hospital from the University of 
Brasília, Brasília, Federal District, in Brazil. The Hospital from 
the University of Brasília is a general hospital attending main-
ly the low-income population originating from the outskirts 
and suburban regions of the city of Brasília. Racially, this is a 
predominantly mixed-blood population in which a consider-
able contribution of European ancestry can be detected in 
association with variable proportions of other races, mainly 
Black African and, to a lesser extent, Amerindian.
This study received approval from the Ethics Committee of 
the School of Health Sciences from the University of Brasília, 
and informed consent for participation in the study and for 
publication of the results was obtained from all the eligible 
adult patients or, in the case of children or adolescents, from 
their parents or guardians.
Among the 211 biopsy-proven celiac patients who were 
included in this study, there were 66 males and 145 females 
(age range: 1 to 48 years-old; mean age: 15.7 years-old). These 
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patients had been diagnosed as presenting CD, in accordance 
with the revised criteria of the European Society of Pediatric 
Gastroenterology and Nutrition (ESPGAN)24. All the celiac pa-
tients were evaluated, and members of their families agreed 
to answer questions, as indicated in the DSM-IV, concerning 
the possible existence of behavioral abnormalities suggestive 
of ASD. 
A small proportion of the patients with ASD was identi-
fied through two local societies of parents of autistic children. 
A larger proportion was found among students in special ed-
ucation classes organized by the Federal District Department 
of Education. The socioeconomic strata and racial character-
istics of the ASD patients were comparable with those of the 
study group of celiac patients. Among the 147 ASD patients 
who were enrolled in the study, there were 127 males and 20 
females (age range: 1 to 35 years-old; mean age, 8 years-old). 
All the patients were diagnosed by accredited medical profes-
sionals and fulfilled the diagnostic criteria of the DSM-IV for 
ASD. None of the patients was on a gluten-free diet (GFD). 
Blood samples were centrifuged, and the resulting sera 
were stored at -20° C until their use. To exclude individuals 
with a possible IgA deficiency, IgA levels were measured by 
turbidimetric immunoquantification (COBAS MIRA, Roche 
Diagnostic Systems). IgA and IgG antigliadin antibodies (IgA-
AGA and IgG-AGA) and IgA anti-transglutaminase antibod-
ies (IgA-tTG) were assessed by means of the standard ELISA 
(Quanta LiteTM IgA and IgG gliadin and human IgA-tTG, 
INOVA Diagnostic, Inc. CA, USA). According to the manufac-
turer’s instructions, the upper limit of the normal range was 
established as 20 arbitrary units. All patients who displayed 
values above the upper limit in the antigliadin or anti-trans-
glutaminase tests underwent further testing for the pres-
ence of anti-endomysium-specific antibodies (IgA-EMA). 
The IgA-EMA assay was performed using indirect immuno-
fluorescence with cryosections of distal monkey esophagus 
(Binding Site, Birmingham, UK). Two independent observers 
examined all the slides, and the presence of brilliant green re-
ticulin-like staining of smooth muscle under the fluorescence 
microscope was considered a positive result. In the present 
study, the IgA-tTG test (more sensitive but less specific) was 
used as a preliminary screening test, while the IgA-EMA one 
was considered a confirmatory test.
statistical analysis
The prevalence of CD and ASD and the increased level of 
IgA-AGA were estimated together with their exact binomi-
al 95% confidence intervals (95%CI). To compare the preva-
lence between groups, the exact p-value for the χ2 statistic 
was calculated (based on binomial distribution). 
results
Among the 147 ASD patients, five displayed abnormal 
results in the IgA-AGA test, and one showed a weakly posi-
tive result in the IgA-tTG test. These six patients were subse-
quently tested for the presence of IgA-EMA with negative re-
sults. The test results and clinical data on these patients can 
be seen in Table 1. 
Among the 211 biopsy-proven CD patients followed at the 
Walk-in CD Clinic of the Hospital from University of Brasília, 
two cases of ASDs were identified: an 11-year-old boy who 
fulfilled all of the DSM-IV criteria for an autistic disorder and 
a seven -year-old boy with Asperger’s syndrome. Both pa-
tients had been referred by their attending physicians due 
to the presence of gastrointestinal symptoms, mainly com-
posed of frequent abdominal cramps and diarrheic episodes. 
A GFD was strictly followed only by one of the two patients, 
who showed progressive improvement in gastrointestinal 
symptoms, although no behavioral improvement could be 
detected. 
Since no data on the prevalence of ASDs in Brazil are 
available as a reference for the prevalence of ASDs in the 
general population, we used the prevalence found by the 
latest surveillance summaries of Center of Disease Control 
(CDC) autism and development disabilities monitoring net-
work, United States, which was conducted in a population 
of 307,790 eight-year-old children3. The prevalence of ASDs 
in patients with CD was 0.95% (95%CI=0.11–3.82) and it was 
not statistically different from the prevalence of 0.9% found 
in the general US population (p=1.00), as seen in Table 2.
No cases of CD were found among the 147 patients with 
ASD. The reference group, regarding the prevalence of CD in 
our area, was composed of 2,034 children younger than 15 
years-old (age range: 1 to 14 years-old; mean age: 8 years-old), 
Patients Sex Age (y) IgG-AGA IgA-AGA IgA-tTG IgA-EMA Symptoms
1 M 14 45.1 9.9 10.9 Negative No gastrointestinal symptoms
2 M 15 3.0 38.8 8.9 Negative No gastrointestinal symptoms
3 M 6 3.4 15.3 29.3 Negative Constipation and occasional diarrhea
4 M 4 12.7 50.6 12.6 Negative No gastrointestinal symptoms
5 M 5 5.1 44.1 6.3 Negative Anemia, constipation, bloating, abdominal 
cramps, mouth ulcers, and chronic fatigue
6 F 12 6.8 45.4 8.8 Negative Constipation and occasional abdominal cramps
ASD: autism spectrum disorder; M: masculine; F: feminine.
Table 1. Clinical and laboratory data on the six ASD patients with abnormal results from serological tests.
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who were part of a previous CD prevalence screening study 
that we conducted, originating from the same geographical 
region and pertaining to a low-income population similar to 
the celiac group of this study. The prevalence of CD in this 
group was 0.54% and no cases of ASD were found among such 
children. Consequently, the prevalence of CD in patients with 
ASD was 0.00% (95%CI=0.00–2.48) and it was not statistically 
different from the prevalence found in children in the same 
region (Table 3). 
To evaluate the possible existence of gluten sensitivi-
ty in ASD patients, we used a reference group consisting of 
132 children who displayed varying degrees of gastrointes-
tinal symptoms (age range: 1 to 12 years-old; mean age: 5.8 
years-old), and who were part of an ongoing study on the 
prevalence of IgA-AGA in non-celiac (IgA-EMA and IgA-tTG 
negative) children. The prevalence of IgA-AGA among these 
children, originating from the same geographical region and 
socioeconomic stratum, was 9.3%, while the prevalence of 
IgA-AGA in patients with ASD was 3.4% (95%CI=1.11–7.76), 
with p=0.08 (Table 4).
DiscussioN 
As previously stated, the wide phenotypic heterogeneity 
suggests that ASDs may possibly encompass several differ-
ent specific disorders with different etiologies sharing a com-
mon behavioral clinical picture. The presently available data 
point towards probable involvement of multiple interacting 
genes and environmental modifiers in the pathogenesis of 
autism25. 
The suggestion that CD might be involved in the patho-
genesis of autism has mostly been based on the leaky-gut hy-
pothesis, i.e., abnormal intestinal mucosa would permit ex-
cessive absorption of short-chain peptides produced from 
incomplete digestion of dietary gluten in the lumen of the 
small intestine, through defective action of peptidases. These 
short peptides, structurally similar to endorphin, could pro-
voke an immune reaction or act as exorphins, thereby direct-
ly affecting the nervous system. However, a recent consensus 
report concluded that the evidence for abnormal gastrointes-
tinal permeability in individuals with ASDs is presently limit-
ed and additional properly powered prospective studies with 
appropriate controls are needed in order to determine the 
role of abnormal permeability in neuropsychiatric manifesta-
tions of ASDs16. Several authors have reported that children 
with ASDs may experience more constipation, loose stools, 
recurrent abdominal pain, bloating, and excessive flatulence 
than presented by non-affected children18,26. 
Although gastrointestinal problems in individuals with 
ASDs may go undiagnosed because of atypical symptoms 
and/or difficulties in communicating with nonverbal pa-
tients, it is difficult to establish whether their prevalence is 
higher than is seen in the general population, due mainly to 
the lack of prospective well-controlled studies. The presumed 
association between an excess of gastrointestinal symptoms 
in children with autism and worsening of their behavior often 
results in implementation of restrictive diets, mainly targeting 
Table 2. Prevalence of ASDs found among our 211 biopsy-proven celiac disease patients, and estimated prevalence of ASDs found 
in a population of 307,790 eight-year-old children in the USA3.
Groups n Prevalenceof ASDs 95%CI
* p-value
(between groups)†
Prevalence of ASDs among our celiac patients 211 0.95 (0.11–3.82) 1.00
Prevalence of ASDs in the USA population (307,790) 0.90
*Based on binomial distribution; †Exact test; Post-hoc power analysis=1.000; ASD: autism spectrum disorder.
Table 3. Prevalence of CD among our 147 ASD patients and in a group of 2,034 children and adolescents originating from the same 
geographical region and from a similar low-income stratum.
Groups n CD prevalence 95%CI* p-value(between groups)†
Prevalence of CD among ASD patients 147 0.00 (0.00–2.48) 0.63
Prevalence of CD among subjects without ASDs 2034 0.54
*Based on binomial distribution; †Exact test; Post-hoc power analysis=0.999993; ASD: autism spectrum disorder; CD: celiac disease.
Table 4. Prevalence of IgA-AGA in ASD patients and in 132 non-celiac children originating from the same geographical region and 
from a similar low-income stratum.
Groups n IgA-AGA Prevalence 95%CI
* p-value
(between groups)†
Prevalence of IgA-AGA in patients with ASDs 147 3.4 (1.11–7.76) 0.08
Prevalence of IgA-AGA in non-celiac patients without ASDs 131 9.3
*Based on binomial distribution; †Exact test; Post-hoc power analysis=0.978618; ASD: autism spectrum disease.
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casein and gluten in the hope of improving their symptoms. 
Several studies and reviews have addressed the topic of the 
existence of a possible gut-to-brain connection and the ef-
fects of dietary intervention in autism, with varying results17. 
In a recent extensive literature review on this topic, Millward 
et al.27 concluded that the current body of evidence to sug-
gest that dietary therapy approaches are effective is still poor, 
and that large-scale, good-quality randomized controlled tri-
als are needed.
The assumption that gastrointestinal symptoms are ex-
cessively frequent in autistic children has raised the hypoth-
esis that greater prevalence of CD could also exist among 
patients with autism, given that one possible point in com-
mon between these two very different diseases would be the 
increased intestinal permeability, which is present in both 
disorders. However, the results from the few studies on the 
possible association between CD and autism have not shown 
consistent results20-23. 
Additionally, as appropriately noted by Lionetti et al.28, it 
is important to remember that autism is a neurological dis-
order of early brain development and therefore it is difficult 
to establish a temporal correlation between the presence of 
abnormalities of the central nervous system and the gluten 
intake, which usually begins after the first six months of age. 
In the majority of children with diagnosis of autism, careful 
analysis on their histories will reveal that the symptoms be-
gan before they reached 18 months of age. This early onset 
only provides a limited period of time for the infant to have 
begun to consume gluten-containing foods. 
Our results showed that the prevalence of CD in patients 
with autism was not greater than the prevalence found in a 
group of 2,034 healthy children originating from the same 
geographical area. We also found that the prevalence of au-
tism was not significantly greater among our group of 211 
biopsy-confirmed CD patients. The possibility of higher glu-
ten sensitivity in ASD children, which would be substanti-
ated by increased presence of IgA-AGA, was also ruled out 
since there was no significant difference in the prevalence of 
these antibodies in comparison with the prevalence found in 
a sample of 131 non-celiac children of similar socioeconomic 
level originating from the same city. 
In conclusion, although the profusion of studies report-
ing clinical and, especially, behavioral improvement with glu-
ten-exclusion diets in patients with autism cannot be simply 
ignored, it is at present difficult to statistically demonstrate 
that there is an association between ASD and CD or between 
ASD and gluten sensitivity. The reported deleterious effects 
on brain function, the behavior of children with ASD, con-
sequent to gluten intake, and the frequently reported clini-
cal improvement with restriction diets, if present, are possi-
bly due to other and not completely clarified mechanisms. In 
the case of gluten sensitivity, in the absence of reliable bio-
markers, the diagnosis is still dependent on establishing an 
exclusion diet in patients who experience distress when eat-
ing gluten-containing products29. 
With the present data, we are forced to agree with the pre-
vious work by Pavone et al.23, who concluded that concomi-
tant occurrences of autism and CD in the same individuals 
are most likely due to pure coincidence. 
Although we feel that performing routine screening for 
CD in all patients with ASD is neither justified nor cost-ef-
fective, one should also consider that CD is a disease with 
reliable serological and genetic markers, whereas the ASD di-
agnosis is based on clinical grounds probably encompassing 
different disorders with a common clinical expression. It is 
possible that different results would have been obtained if a 
specific subset of ASD patients had been selected (e.g., only 
children with regressive autism). 
The main limitation of the present paper is that even 
though both disorders are lifelong conditions, the age of on-
set of the CD is variable and some of the ASD patients could 
still develop this disease in the future. Another limitation is 
that although the source of all patients with ASDs were re-
gional societies of parents of autistic children and all diagno-
ses had been made by accredited medical professionals, we 
were only able to perform a complete evaluation in person 
on a subset of these patients. It is possible that other clinical 
entities (e.g. fragile X syndrome) could have been included in 
the group of ASD patients. Additionally, due to the complete 
lack of data regarding the prevalence of ASDs in Brazil, we 
used the prevalence of ASD in the USA based on the latest 
CDC report3, as a reference point for statistical analysis. 
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